Quris-AI, an artificial intelligence innovator disrupting the pharmaceutical arena, announced the extension of its collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.
Companies Extend Collaboration After Successful Preclinical Study Assessed the Quris-AI BioAI Drug Safety Platform
BOSTON and TEL AVIV, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Quris-AI, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced the extension of its collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company. This follows the successful initial collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison to traditional in vitro and in vivo approaches.
Merck KGaA, Darmstadt, Germany will now further leverage Quris-AI platform’s ability to effectively identify liver toxicity risks in a selection of drug candidates. Subsequently, Merck KGaA, Darmstadt, Germany has the option to obtain up to a five-year exclusive license to a specific disease domain. Upon Merck KGaA, Darmstadt, Germany exercising the option, Quris-AI may receive an undisclosed amount.
“Based on the results of our initial collaboration, we are looking forward to exploring how its BioAI platform can advance our drug development and testing programs, and working towards an AI-enabled IND process that reduces the reliance on animal testing,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck KGaA, Darmstadt, Germany. “If we could better focus on developing safe and effective drug candidates, we would be able to reduce significant time and cost investments.”
The preclinical pilot study demonstrated that Quris-AI’s platform could accurately predict which drug caused drug induced liver injury. The Quris-AI BioAI platform (29 granted and pending patents) delivers best-in-class drug safety, through its advanced machine learning and generative AI models, which are trained on Quris-AI’ highly predictive, proprietary data, generated from its AI-based patient-on-chip platform. This dramatically accelerates and cuts costs of drug development, and avoids the potentially disastrous pitfalls of traditional animal testing.
“The majority of drug candidates still fail once they reach clinical testing. Technology advances are fueling a much-needed transformation in drug development,” said Dr. Isaac Bentwich, CEO of Quris-AI. ”Accurately predicting the safety of novel drugs will significantly increase the speed of drug innovation and time to market, while substantially reducing risks and associated costs. We look forward to our ongoing partnership with Merck KGaA, Darmstadt, Germany, as we continue to advance the field of pharmaceutical research.”
Watch this video for perspective on how Quris-AI is reshaping the drug development process, a recent NYSE-TV interview, or Quris-AI’s inaugural Impact Review (ESG/SDG) for more details on the company’s global impact.
ABOUT QURIS-AI
Quris-AI, the world’s first BioAI clinical-prediction platform, ensures the safety of new drugs. Revolutionizing the drug development process, the company is pioneering clinical trials on chips – testing thousands of novel drug candidates on hundreds of miniaturized “patients-on-a-chip”. Its fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost effectively than ever before – all while minimizing animal testing. Dual-headquartered in Boston and Israel and backed by strategic biotech and big data investors, Quris-AI is led by a proven team of AI and medical research powerhouses. For more information, visit www.quris.ai.
Media Contact:
Erica Camilo
Connexa Communications for Quris-AI
1.610.639.5644
erica@connexacommunications.com
